RxDoctor Payments Data

Michael Schwartz, DO

Psychiatry · Costa Mesa, CANPI 1861584708

Payments from drug & device makers

$2,572in general payments, 2019–2025

Across 115 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$788
  • Neurocrine Biosciences, Inc.$382
  • Teva Pharmaceuticals USA, Inc.$364
  • Otsuka America Pharmaceutical, Inc.$354
  • Indivior Inc.$231
  • E.r. Squibb & Sons, L.L.C.$173
  • plus $281 from 5 others

What the payments were for

  • Food & beverage$2,54599%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,572 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$89,395
Medicare patients
97
Services billed
1,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine43$302,901
Invega SustennaPaliperidone Palmitate36$124,986
VraylarCariprazine Hcl24$32,564
Lurasidone Hcl30$15,370
TrintellixVortioxetine Hydrobromide16$7,990
Clozapine149$6,760
Paliperidone ErPaliperidone13$5,647
BelsomraSuvorexant12$4,804
Quetiapine Fumarate135$2,823
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl13$1,757
Aripiprazole51$1,397
Divalproex Sodium97$1,313
Olanzapine83$1,274
Gabapentin135$1,169
Hydroxyzine Pamoate110$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$364$302,90143 claims
Johnson & JohnsonInvega Sustenna$82$124,98636 claims
AbbVieVraylar$47$32,56424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Costa Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →